IVI-RMA | AI Transformation Index

Overview

IVI-RMA Global is a leading fertility clinic network that delivers assisted reproductive treatments (IVF, egg donation, fertility preservation, artificial insemination) on a fee-for-service basis across 190+ clinical offices in 15+ countries.

Executive Summary

IVI-RMA is one of the most structurally durable healthcare assets in a PE portfolio: its core value delivery is physically and clinically irreducible, its regulatory and capex moats are deep, and patient trust in fertility treatment creates genuine switching costs that AI cannot erode. The AI opportunity is real but focused — the business has built proprietary embryo outcome data and clinical decision-support tools that can improve success rates and specialist throughput across its expanding global network, making AI a capability amplifier rather than a disruptor. For KKR, the strategic question is how aggressively to deploy AI-driven clinical intelligence across newly acquired clinics in India and the UAE, where standardizing protocols using IVI-RMA's proprietary data could drive both outcome differentiation and margin expansion at scale.

Durability Rationale

IVI-RMA is structurally very durable against AI disruption because its core value delivery is physically and clinically embodied — no LLM or AI agent can perform an egg retrieval, culture embryos, or execute an embryo transfer. The business operates in a heavily regulated clinical environment requiring licensed physicians, certified embryology labs, and accreditation frameworks that create near-insurmountable barriers to AI-native entry. Patient trust and emotional stakes during fertility treatment create powerful switching costs, and the global clinic network represents a physical footprint that compounds over decades, not quarters. The primary durability risk is margin compression at the periphery — if AI-native patient acquisition platforms capture the initial patient relationship — but the high-value procedural core is structurally protected.

Opportunity Rationale

The most significant AI opportunity for IVI-RMA lies in amplifying its proprietary domain intelligence — decades of reproductive medicine expertise and a massive proprietary embryo outcome dataset represent a rare asset that AI compute can systematically unlock. AI-assisted embryo selection and stimulation optimization are already producing measurable clinical improvements, and the unrealized opportunity to extend these capabilities more broadly across the network (particularly newly acquired clinics in India and emerging markets) is substantial. The transformation upside is partially constrained by physical throughput limits inherent in clinical medicine, but AI can meaningfully increase the effective capacity of scarce specialist talent — allowing senior embryologists and reproductive endocrinologists to supervise more cases and deliver more consistent outcomes across a global footprint.

Key Risks